Endotyping idiopathic pulmonary fibrosis should improve outcomes for all patients with progressive fibrotic lung disease

作者
Gisli R. Jenkins
出处
期刊:Thorax [BMJ]
卷期号:70 (1): 9-10 被引量:3
标识
DOI:10.1136/thoraxjnl-2014-206209
摘要

The first few years of the current millennium has seen a paradigm shift in the way people view idiopathic pulmonary fibrosis (IPF). In 2004, Raghu et al 1published the first multicentre, double blind, randomised, placebo-controlled trial in IPF. Although a negative study, it taught the field much about the natural history and conduct of clinical trials in IPF. Ultimately, this study paved the way for the Clinical Studies Assessing Pirfenidone in idiopathic pulmonary fibrosis: Research of Efficacy and Safety Outcomes (CAPACITY) studies2 that lead to the approval of Pirfenidone in Europe and eventually the Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND)3 and Prospective Observation of Fibrosis in the Lung: Clinical Endpoints (IMPULSIS)4 studies, which might lead to approval for the use of two disease-modifying drugs for the treatment of IPF in both the USA and Europe. Any thought at the turn of the century that progressive fibrotic lung disease, in the absence of inflammation, might be modifiable would have been regarded with a fair degree of scepticism. The field has come far. However, the journey has only just begun. Extrapolating data from recent epidemiological studies would suggest there has been approximately a doubling of the incidence of IPF and associated healthcare requirements since the turn of the century.5 ,6 Furthermore, patients enrolled into clinical trials represent a unique subpopulation of patients with IPF, itself a subpopulation of patients …

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
DW的应助被Jyouang采纳,获得10
1秒前
香蕉觅云的应助被Sussie采纳,获得10
1秒前
何显扬完成签到,获得积分10
1秒前
医生不吹蜡烛完成签到,获得积分10
1秒前
ding的应助被Sussie采纳,获得10
1秒前
1秒前
CJB完成签到,获得积分20
2秒前
small_LL发布了新的文献求助10
2秒前
Liyt11发布了新的文献求助10
2秒前
Maestro_S的应助被芋圆采纳,获得10
2秒前
2秒前
2秒前
2秒前
云清完成签到,获得积分20
2秒前
orixero的应助被lk采纳,获得10
2秒前
桐桐的应助被鼠条采纳,获得10
3秒前
小马哥发布了新的文献求助10
3秒前
songsong完成签到 ,获得积分10
3秒前
开心黑米完成签到,获得积分10
3秒前
猪猪hero发布了新的文献求助10
3秒前
藿香完成签到,获得积分10
3秒前
虚幻的垣发布了新的文献求助10
3秒前
年轻人发布了新的文献求助10
4秒前
4秒前
5秒前
kido完成签到,获得积分10
5秒前
5秒前
5秒前
6秒前
6秒前
高兴香水发布了新的文献求助10
6秒前
6秒前
Yuuki完成签到,获得积分10
6秒前
7秒前
锋回露转123完成签到,获得积分10
7秒前
Akim的应助被dzx采纳,获得10
7秒前
科研通AI65的应助被Jyouang采纳,获得10
7秒前
8秒前
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176174
求助须知:如何正确求助?哪些是违规求助? 9567656
关于积分的说明 21793895
捐赠科研通 7770887
什么是DOI,文献DOI怎么找? 3431991
关于科研通互助平台的介绍 2556313
邀请新用户注册赠送积分活动 2477540